Ozone effects on inhibitors of human neutrophil proteinases
Research article published in Arch Biochem Biophys (1987)
Resumen
The effects of ozone on human alpha 1-proteinase inhibitor (A-1-PI), alpha 1-antichymotrypsin (A-1-Achy), bronchial leukocyte proteinase inhibitor (BLPI), and Eglin C were studied using in vitro exposures in phosphate-buffered solutions. Following ozone exposure, inhibitory activities against human neutrophil elastase (HNE) and/or cathepsin G (Cat G) were measured. Exposure of A-1-PI to 50 mol O3/mol protein resulted in a complete loss of HNE inhibitory activity, whereas A-1-Achy lost only 50% of its Cat G inhibitory activity and remained half active even after exposure to 250 mol of O3. At 40 mol O3/mol protein, BLPI lost 79% of its activity against HNE and 87% of its Cat G inhibitory activity. Eglin C, a leech-derived inhibitor, lost 81% of its HNE inhibitory activity and 92% of its ability to inhibit Cat G when exposed to 40 mol O3/mol. Amino acid analyses of ozone-exposed inhibitors showed destruction of Trp, Met, Tyr, and His with as little as 10 mol O3/mol protein, and higher levels of O3 resulted in more extensive oxidation of susceptible residues. The variable ozone susceptibility of the different amino acid residues in the four proteins indicated that oxidation was a function of protein structure, as well as the inherent susceptibility of particular amino acids. Exposure of A-1-PI and BLPI in the presence of the antioxidants, Trolox C (water soluble vitamin E) and ascorbic acid (vitamin C), showed that antioxidant vitamins may protect proteins from oxidative inactivation by ozone. Methionine-specific modification of BLPI reduced its HNE and Cat G inhibitory activities. Two moles of N-chlorosuccinimide per mole of BLPI methionine caused an 80% reduction in activity against Cat G, but only a 40% reduction in HNE inhibitory activity.
Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.
El resumen se deja sin traducir para conservar la redacción original de los autores.
Síntesis
Ozone exposure inactivated four human neutrophil protease inhibitors (A-1-PI, A-1-antichymotrypsin, BLPI and Eglin C) to different degrees by destroying susceptible amino acids, and antioxidant vitamins may protect such proteins from this oxidative inactivation.
Por qué esto importa para la hirudoterapia
Este estudio in vitro examinó los efectos de la exposición al ozono sobre cuatro inhibidores de proteinasas de neutrófilos humanos —inhibidor de alfa 1-proteinasa, alfa 1-antiquimotripsina, inhibidor de proteinasa de leucocitos bronquiales, y Eglin C (descrito en el resumen como un inhibidor derivado de la sanguijuela)— en soluciones tamponadas con fosfato, midiendo la actividad residual frente a la elastasa de neutrófilos y la catepsina G. Eglin C perdió el 81% de su actividad inhibidora de elastasa y el 92% de su actividad inhibidora de catepsina G a 40 mol O3/mol de proteína, con la oxidación destruyendo residuos de Trp, Met, Tyr e His en las proteínas analizadas; los autores informan que las vitaminas antioxidantes (Trolox C, ácido ascórbico) pueden proteger a las proteínas de la inactivación oxidativa. La identificación de Eglin C como inhibidor derivado de la sanguijuela otorga a este estudio un vínculo bioquímico con proteínas derivadas de la sanguijuela. ADVERTENCIA: Se trata de un estudio bioquímico in vitro que utiliza inhibidores purificados; no involucra sanguijuelas, hirudoterapia ni el secretoma intacto de la sanguijuela, y no formula afirmaciones terapéuticas.
Compuestos relacionados del registro de la ASH
Moléculas de la sanguijuela y fármacos derivados de la hirudina relacionados con el tema de este artículo, cada uno con un perfil completo en el registro de compuestos de la ASH:
Citación
Ozone effects on inhibitors of human neutrophil proteinases.
Smith CE et al. · Arch Biochem Biophys, 1987
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Investigación relacionada
Más estudios revisados por pares en la categoría «Farmacología salival».
- Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
- Leech Salivary Proteome and Transcriptome: 434 Deduced Protein Sequences — Liu Z, Tong X, Su Y, et al. (2019)
- Medicinal Leech Draft Genome — Anticoagulant Gene Survey — Kvist S, Manzano-Marín A, de Carle D, Trontelj P, Siddall ME (2020)
- Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
- Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
- Medicinal leeches and hirudotherapy — Gödekmerdan A et al. (2011)
- PEROXIDATION OF SALIVA LIPIDS IN PATIENTS WITH POSTCOVID SYNDROME DURING HIRUDOTHERAPY — Serikbayeva S et al. (2024)
- Medicinal leech therapy in pain syndromes: a narrative review — Koeppen D, Aurich M, Rampp T (2014)
- Leech therapy in the treatment of a penile haematoma in a stallion — Nowicki A, Jaworska J, Baranski W (2021)
- Leech therapy (Hirudo medicinalis) attenuates testicular damages induced by testicular ischemia/reperfusion in an animal model — Davoodi F et al. (2021)
Añadido a la biblioteca ASH: 27 de mayo de 2026 · Última actualización del sitio: 18 de junio de 2026